Loading
Proposed cancer immunoediting and showed neoantigens are the targets of checkpoint immunotherapy.
Robert D. Schreiber is the Andrew M. and Jane M. Bursky Distinguished Professor and Director of the Bursky Center for Human Immunology and Immunotherapy Programs at Siteman Cancer Center, Washington University. He is an immunologist who proposed the three-phase model of cancer immunoediting and showed that mutant neoantigens are the targets of checkpoint immunotherapy. His selected paper shows that checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. He continues to work on neoantigens, interferon-gamma and the immune control of cancer.
| Title | Journal | Year |
|---|---|---|
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Nature | 2014 |
| Schreiber, Old and Smyth 2011: cancer immunoediting | Science | 2011 |
Shares Siteman Cancer Center, Washington University, Neoantigen.
Shares Schreiber, Old and Smyth 2011: cancer immunoediting, Neoantigen, Immune checkpoint inhibitors.
Shares Immune surveillance and cancer immunoediting, Neoantigen, Immune checkpoint inhibitors.
Shares Neoantigen, Immune checkpoint inhibitors.
Shares Neoantigen, Immune checkpoint inhibitors.
Shares Schreiber, Old and Smyth 2011: cancer immunoediting, Immune surveillance and cancer immunoediting, Immune checkpoint inhibitors.
Shares Siteman Cancer Center, Washington University, Neoantigen.
Shares Immune surveillance and cancer immunoediting, Immune checkpoint inhibitors.